INNT Market Cap History
Below is a table of the INNT market cap history going back to 2/1/2018:

Date INNT Market Cap

Also see: INNT Shares Outstanding History
and INNT YTD Return
INNT Historical Market Cap:
+77.22% CAGR
INNT Historical Market Cap: +77.22% CAGR

Mouse over chart for data details
Innovate Biopharmaceuticals a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. Co.'s pipeline includes drug candidates for celiac disease, nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis, Crohn's disease and ulcerative colitis (UC). Co.'s key program, INN-202 (larazotide acetate or larazotide) is entering Phase 3 registration trials for celiac disease. Co. is also developing larazotide for the treatment of NASH (INN-217), a smaller subset of liver disease stemming from the fatty liver disease. INN-108 is an oral small molecule therapeutic for UC. Co. owns the global rights to INN-329, a key formulation of secretin. We show 10 historical shares outstanding datapoints in our INNT shares outstanding history coverage, used to compute INNT market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing INNT market cap history over the course of time is important for investors interested in comparing INNT's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of INNT versus a peer is one thing; comparing INNT market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like INNT can fluctuate over the course of history. With this page we aim to empower investors researching INNT by allowing them to research the INNT market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for INNT:
INNT SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Innovate Biopharmaceuticals (INNT) is categorized under the Miscellaneous sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

INSP Market Cap History
INSU Market Cap History
INSW Market Cap History
INTF Market Cap History
INTZ Market Cap History
INVO Market Cap History
INZY Market Cap History
IPA Market Cap History
IPIC Market Cap History
IPOA Market Cap History
More Miscellaneous companies »


INNT Market Cap History | | Copyright © 2017 - 2021, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.